Moreover, while HMGB1 capacity to stimulate EXO1 activity and bridge MMR-NER complexes suggests possible implications for therapy resistance, direct evidence linking HMGB1-mediated MMR modulation to therapy resistance remains lacking, warranting further mechanistic investigation in cancer-relevant systems. Here, HMGB1 is linked to cancer.